Outset Medical Reports Third-Quarter 2026 Revenue of $33.6 Million
Revenue increased 14% year over year. Net loss narrowed to $14.7 million, diluted loss per share improved to $0.78, and gross margin rose 130 basis points to 40.7%. The company reiterated full-year 2026 revenue guidance of $125 million to $130 million.
Outset Medical reported third-quarter 2026 revenue of $33.6 million, representing a 14% increase compared to the same period in 2025. The company's net loss narrowed to $14.7 million from $17.8 million in the prior-year quarter, with diluted loss per share improving to $(0.78) from $(1.00). Gross margin expanded to 40.7%, an increase of 130 basis points year-over-year, driven by cost efficiencies and stronger service margins. Outset Medical reiterated its full-year 2026 revenue guidance of $125 million to $130 million.
Management highlighted continued growth opportunities in console refreshes, customer expansion, and home dialysis support.